BR112018009954A2 - materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias - Google Patents
materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatiasInfo
- Publication number
- BR112018009954A2 BR112018009954A2 BR112018009954A BR112018009954A BR112018009954A2 BR 112018009954 A2 BR112018009954 A2 BR 112018009954A2 BR 112018009954 A BR112018009954 A BR 112018009954A BR 112018009954 A BR112018009954 A BR 112018009954A BR 112018009954 A2 BR112018009954 A2 BR 112018009954A2
- Authority
- BR
- Brazil
- Prior art keywords
- titin
- methods
- materials
- titinopathies
- myopathies
- Prior art date
Links
- 108010002947 Connectin Proteins 0.000 title abstract 4
- 102000004726 Connectin Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000021642 Muscular disease Diseases 0.000 title abstract 2
- 201000009623 Myopathy Diseases 0.000 title abstract 2
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 238000010362 genome editing Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
o presente pedido proporciona materiais e métodos para tratar um doente com uma miopatia baseada em titina, particularmente uma cardiomiopatia baseada em titina e / ou outra titinopatia. além disso, o presente pedido fornece materiais e métodos para editar o gene da titina numa célula por edição do genoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562255887P | 2015-11-16 | 2015-11-16 | |
PCT/US2016/062052 WO2017087395A1 (en) | 2015-11-16 | 2016-11-15 | Materials and methods for treatment of titin-based myopathies and other titinopaties |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018009954A2 true BR112018009954A2 (pt) | 2018-11-13 |
Family
ID=58717720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018009954A BR112018009954A2 (pt) | 2015-11-16 | 2016-11-15 | materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias |
Country Status (15)
Country | Link |
---|---|
US (2) | US11617783B2 (pt) |
EP (1) | EP3377042A4 (pt) |
JP (3) | JP7418957B2 (pt) |
KR (1) | KR20180081600A (pt) |
CN (1) | CN108463211B (pt) |
AU (1) | AU2016358172B2 (pt) |
BR (1) | BR112018009954A2 (pt) |
CA (1) | CA3005633C (pt) |
CO (1) | CO2018006133A2 (pt) |
EA (1) | EA201891192A1 (pt) |
HK (1) | HK1257955A1 (pt) |
IL (1) | IL259441B2 (pt) |
MX (1) | MX2018006116A (pt) |
SG (1) | SG11201804166YA (pt) |
WO (1) | WO2017087395A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
CA3002827A1 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
GB2573062A (en) | 2016-10-14 | 2019-10-23 | Harvard College | AAV delivery of nucleobase editors |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
BR112019019655A2 (pt) | 2017-03-23 | 2020-04-22 | Harvard College | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
SG11202012715UA (en) * | 2018-06-29 | 2021-01-28 | Res Inst Nationwide Childrens Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
GB2601618A (en) | 2019-03-19 | 2022-06-08 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
CN113512536A (zh) * | 2021-05-07 | 2021-10-19 | 山东大学深圳研究院 | 一种用于制备人体多巴胺神经元的试剂盒及其应用 |
WO2023190935A1 (en) * | 2022-03-31 | 2023-10-05 | Modalis Therapeutics Corporation | Method for treating myopathies by targeting titin gene |
WO2023212582A2 (en) * | 2022-04-25 | 2023-11-02 | The Jackson Laboratory | Methods for treating dilated cardiomyopathy and pharmaceutical compositions therefor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
ATE272123T1 (de) | 1993-11-09 | 2004-08-15 | Ohio Med College | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
JPH09509564A (ja) | 1993-11-09 | 1997-09-30 | ターゲテッド ジェネティックス コーポレイション | 高力価組換えaavベクターの生成 |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
AU707866B2 (en) | 1994-12-06 | 1999-07-22 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
AU715543B2 (en) | 1995-09-08 | 2000-02-03 | Genzyme Corporation | Improved AAV vectors for gene therapy |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
EP2325299A3 (en) | 1997-09-05 | 2011-10-05 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant AAV vectors |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
WO2007049095A1 (en) * | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
KR101240487B1 (ko) * | 2006-11-09 | 2013-03-08 | 더 존스 홉킨스 유니버시티 | 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화 |
US20110023139A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
FR2962041B1 (fr) | 2010-07-01 | 2012-07-27 | Genethon | Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies |
EP4289948A3 (en) | 2012-05-25 | 2024-04-17 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
TWI677350B (zh) * | 2012-09-25 | 2019-11-21 | 美商健臻公司 | 治療強直性肌失養症之經胜肽連結之嗎啉基反義寡核苷酸 |
US20140179770A1 (en) | 2012-12-12 | 2014-06-26 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US20140189896A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Crispr-cas component systems, methods and compositions for sequence manipulation |
PL2921557T3 (pl) | 2012-12-12 | 2017-03-31 | Broad Inst Inc | Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją |
KR20160034901A (ko) | 2013-06-17 | 2016-03-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물 |
TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
US9850497B2 (en) * | 2013-11-04 | 2017-12-26 | Regents Of The University Of Minnesota | Gene targeting methods and tools |
EP3079726B1 (en) * | 2013-12-12 | 2018-12-05 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
-
2016
- 2016-11-15 JP JP2018525652A patent/JP7418957B2/ja active Active
- 2016-11-15 EP EP16866951.3A patent/EP3377042A4/en active Pending
- 2016-11-15 CA CA3005633A patent/CA3005633C/en active Active
- 2016-11-15 MX MX2018006116A patent/MX2018006116A/es unknown
- 2016-11-15 AU AU2016358172A patent/AU2016358172B2/en active Active
- 2016-11-15 WO PCT/US2016/062052 patent/WO2017087395A1/en active Application Filing
- 2016-11-15 CN CN201680078207.8A patent/CN108463211B/zh active Active
- 2016-11-15 SG SG11201804166YA patent/SG11201804166YA/en unknown
- 2016-11-15 BR BR112018009954A patent/BR112018009954A2/pt active Search and Examination
- 2016-11-15 IL IL259441A patent/IL259441B2/en unknown
- 2016-11-15 KR KR1020187016954A patent/KR20180081600A/ko not_active Application Discontinuation
- 2016-11-15 US US15/776,714 patent/US11617783B2/en active Active
- 2016-11-15 EA EA201891192A patent/EA201891192A1/ru unknown
-
2018
- 2018-06-15 CO CONC2018/0006133A patent/CO2018006133A2/es unknown
-
2019
- 2019-01-09 HK HK19100317.5A patent/HK1257955A1/zh unknown
-
2021
- 2021-10-29 JP JP2021177441A patent/JP2022009734A/ja active Pending
-
2023
- 2023-02-01 US US18/162,850 patent/US20230233651A1/en active Pending
- 2023-11-08 JP JP2023190737A patent/JP2023184679A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016358172A1 (en) | 2018-06-07 |
IL259441A (en) | 2018-07-31 |
SG11201804166YA (en) | 2018-06-28 |
CA3005633A1 (en) | 2017-05-26 |
US20230233651A1 (en) | 2023-07-27 |
AU2016358172B2 (en) | 2023-06-22 |
EP3377042A1 (en) | 2018-09-26 |
JP2018533959A (ja) | 2018-11-22 |
US20180360921A1 (en) | 2018-12-20 |
IL259441B1 (en) | 2023-09-01 |
IL259441B2 (en) | 2024-01-01 |
CN108463211A (zh) | 2018-08-28 |
KR20180081600A (ko) | 2018-07-16 |
US11617783B2 (en) | 2023-04-04 |
JP7418957B2 (ja) | 2024-01-22 |
JP2022009734A (ja) | 2022-01-14 |
WO2017087395A1 (en) | 2017-05-26 |
CA3005633C (en) | 2023-11-21 |
EP3377042A4 (en) | 2019-05-29 |
JP2023184679A (ja) | 2023-12-28 |
CN108463211B (zh) | 2022-09-27 |
MX2018006116A (es) | 2019-04-04 |
HK1257955A1 (zh) | 2019-11-01 |
EA201891192A1 (ru) | 2019-01-31 |
CO2018006133A2 (es) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018009954A2 (pt) | materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias | |
BR112018012894A2 (pt) | materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal | |
BR112018071321A2 (pt) | materiais e métodos para tratamento de hemoglobinopatias | |
BR112018008971A2 (pt) | materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a | |
CL2018000429A1 (es) | Moduladores de la expresión de kras | |
MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
MX2021008281A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
BR112018009717A8 (pt) | ?polinucleotídeo, vetor de vírus adeno-associado, partícula de um vírus adeno-associado, célula hospedeira infectada com uma partícula de vírus adeno-associado, e, métodos para produzir uma partícula de vírus adeno-associado, para tratar a hemofilia a e para transduzir uma célula hospedeira? | |
MX2017001281A (es) | Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo. | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
CR20150217A (es) | Inhibidores de histona demetilasas | |
BR112017003111A2 (pt) | composições e métodos para o tratamento de distúrbios neurológicos | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112016010175A2 (pt) | Repressor genético, seus usos, e composição farmacêutica | |
BR122020024446B8 (pt) | Compostos para modulação da expressão do receptor do hormônio de crescimento | |
BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
BR112018011838A2 (pt) | terapia gênica para distúrbios oculares | |
BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
CO2017001025A2 (es) | Métodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la pérdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes | |
EA201890811A1 (ru) | Способы лечения мышечной дистрофии | |
BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |